These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 3457567

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.
    Trendowski M, Mitchell JM, Corsette CM, Acquafondata C, Fondy TP.
    Invest New Drugs; 2015 Apr; 33(2):290-9. PubMed ID: 25563824
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of cytoskeletal inhibitors on the accumulation of vincristine in a resistant human lung cancer cell line with high level of polymerized tubulin.
    Chan MW, Chiang CD, Song EJ, Yang VC.
    Cancer Biochem Biophys; 1998 Nov; 16(4):347-63. PubMed ID: 9925282
    [Abstract] [Full Text] [Related]

  • 7. Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
    Trendowski M, Christen TD, Acquafondata C, Fondy TP.
    BMC Cancer; 2015 Sep 10; 15():632. PubMed ID: 26357852
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement.
    Naito M, Tsuruo T.
    Cancer Res; 1989 Mar 15; 49(6):1452-5. PubMed ID: 2924298
    [Abstract] [Full Text] [Related]

  • 10. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1981 May 15; 41(5):1967-72. PubMed ID: 7214365
    [Abstract] [Full Text] [Related]

  • 11. Difference in effects of alkyl-lysophospholipids and verapamil on vincristine transport in vincristine-sensitive and -resistant human myelogenous leukemia K562.
    Tsuruo T, Saito H.
    Anticancer Res; 1987 May 15; 7(1):39-43. PubMed ID: 3471174
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of vincristine by vitamin A against drug-resistant mouse leukaemia cells.
    Nogae I, Kikuchi J, Yamaguchi T, Nakagawa M, Shiraishi N, Kuwano M.
    Br J Cancer; 1987 Sep 15; 56(3):267-72. PubMed ID: 3663474
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of glucose transport inhibitors on vincristine efflux in multidrug-resistant murine erythroleukaemia cells overexpressing the multidrug resistance-associated protein (MRP) and two glucose transport proteins, GLUT1 and GLUT3.
    Martell RL, Slapak CA, Levy SB.
    Br J Cancer; 1997 Sep 15; 75(2):161-8. PubMed ID: 9010020
    [Abstract] [Full Text] [Related]

  • 15. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.
    Chiang CD, Song EJ, Yang VC, Chao CC.
    Biochem J; 1994 Aug 01; 301 ( Pt 3)(Pt 3):759-64. PubMed ID: 7914401
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
    Ganapathi R, Grabowski D, Schmidt H.
    Biochem Pharmacol; 1986 Feb 15; 35(4):673-8. PubMed ID: 3947398
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of antiproliferation activity of vincristine and adriamycin by interferon.
    Kataoka T, Oh-Hashi F, Sakurai Y.
    Gan; 1984 Jun 15; 75(6):548-56. PubMed ID: 6540725
    [Abstract] [Full Text] [Related]

  • 19. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
    Sehested M, Bindslev N, Demant EJ, Skovsgaard T, Jensen PB.
    Biochem Pharmacol; 1989 Sep 15; 38(18):3017-27. PubMed ID: 2571333
    [Abstract] [Full Text] [Related]

  • 20. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
    Bouchelouche P, Friche E, Sehested M, Jensen PB, Skovsgaard T.
    Biochem Pharmacol; 1991 Jan 15; 41(2):243-53. PubMed ID: 1899193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.